Harbor Biotechnology, LLC
____________________________________________
Pharmaceutical Innovation for Treatment of Stroke
We are currently engaged in research and development of:
Pharmaceuticals for the treatment of stroke. In the United States someone develops a stroke every minute, and dies of stroke related complications every 3 minutes. Most strokes are ischemic, due to clot formation in brain blood vessels. An approved treatment is to administer a thrombolytic agent that dissolves the clots. However, thrombolysis must occur during a brief window of opportunity following the initial symptoms of ischemic stroke. If the thrombolytic agent is given too late (after about 3-4 hours), a deadly side-effect may occur involving cerebral bleeding and death! Thus, most patients (about 95%) go untreated, since they do not reach the emergency room in time to be evaluated and safely administered the thrombolytic agent! For this reason, we have been engaged in defining the biological mechanisms responsible for cerebral bleeding associated with thrombolysis for ischemic stroke, and developing pharmacological therapeutics to prevent cerebral hemorrhage and safely prolong the window of opportunity for treatment.
For more information, please enter your request here:
The future is bright.
Harbor Biotechnology, LLC © 2016 | 31 Little Bend Road, Barrington Hills, IL 60010 | harborbiotechnology.com | info@harborbiotechnology.com
